Omeprazole Market Report 2026

The omeprazole market size has grown strongly in recent years. It will grow from $2.5 billion in 2025 to $2.68 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of gastric and duodenal ulcers, rising cases of gastroesophageal reflux disease (gerd), growing awareness of proton pump inhibitors, limited availability of alternative therapies, expansion of hospital and retail pharmacy networks.

The omeprazole market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to rising demand for personalized gastric treatments, growth in online pharmacy channels, technological advancements in drug delivery systems, increasing adoption of omeprazole for pediatric and geriatric populations, expansion of pharmaceutical manufacturing in emerging markets. Major trends in the forecast period include rising adoption of digital health platforms for prescription management, integration of ai in drug formulation and personalized therapy, development of precision medicine approaches for gastrointestinal disorders, automation in pharmaceutical manufacturing and quality control, iot-enabled monitoring of drug storage and distribution.

The rising incidence of gastric cancer is expected to drive the growth of the omeprazole market in the coming years. Gastric cancer refers to malignant tumors that develop in the lining of the stomach. The increase in gastric cancer cases is attributed to factors such as chronic *Helicobacter pylori* infection, excessive alcohol consumption, genetic susceptibility, long-term gastritis, obesity, and regional differences in disease prevalence. Omeprazole, a proton pump inhibitor, supports the management of gastric cancer by lowering stomach acid production, which helps relieve symptoms, improves patient quality of life, and aids in the healing of ulcers or lesions in the stomach lining. For example, in January 2025, the American Cancer Society, a US-based health organization, reported approximately 30,300 new cases of gastric cancer, including 17,720 cases in men and 12,580 cases in women, indicating a higher prevalence among men. In addition, out of nearly 10,780 deaths associated with this cancer, 6,400 occurred in men and 4,380 in women, highlighting a greater mortality burden in the male population. As a result, the increasing incidence of gastric cancer is contributing to the expansion of the omeprazole market.

Leading companies operating in the omeprazole market are focusing on the development of ready-to-use liquid formulations to improve patient convenience and treatment adherence, particularly for individuals who have difficulty swallowing tablets or capsules. Liquid formulations of omeprazole help enhance compliance, improve ease of use, enable accurate dosing, provide quicker onset of action, and maintain improved medication stability. For instance, in February 2024, Alkaloid AD, a North Macedonia-based pharmaceutical manufacturing company, introduced a liquid omeprazole product. This product represents the first ready-to-use liquid omeprazole designed for patients with reflux esophagitis and gastroesophageal reflux disease who are unable to swallow solid dosage forms, and it features a dual-chamber packaging system. The innovation offers a more practical and accessible treatment option for patients such as young children, adults with dysphagia, individuals using gastric feeding tubes, and elderly patients. The company has secured the first international patent for this value-added medicine and has obtained marketing authorizations in both the Macedonian and UK markets.

In February 2025, Epicur Pharma, a US-based veterinary pharmaceutical outsourcing facility, entered into a collaboration with the Bova Group to introduce a patented injectable omeprazole suspension for horses in the United States. Through this partnership, Epicur aims to expand its equine healthcare portfolio by commercializing Bova’s established injectable omeprazole formulation for the treatment of equine gastric ulcers across the US market. Bova Group is a UK-based company specializing in the formulation of injectable omeprazole as a veterinary medicine.

Major companies operating in the omeprazole market are Pfizer Inc., AstraZeneca plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Macleods Pharmaceuticals Pvt Ltd., Perrigo Company plc, Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Aurobindo Pharma, Dr. Reddy's Laboratories, Cipla, Apotex Inc., Amneal Pharmaceuticals, Lupin Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals, Jubilant Generics Limited, Accord Healthcare, Hetero Healthcare Limited, Zydus Cadila, Ranbaxy Laboratories Limited.

North America was the largest region in the omeprazole market in 2025. The regions covered in the omeprazole market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the omeprazole market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the omeprazole market by increasing import costs for raw materials, active pharmaceutical ingredients, and specialized manufacturing equipment, impacting hospital pharmacies, retail pharmacies, and online pharmacies primarily in north america, europe, and asia-pacific. While tariffs may increase operational costs, they also encourage local production, sourcing diversification, and investment in domestic pharmaceutical manufacturing, which could strengthen supply chains and reduce dependence on imports.

The omeprazole market research report is one of a series of new reports that provides omeprazole market statistics, including omeprazole industry global market size, regional shares, competitors with a omeprazole market share, detailed omeprazole market segments, market trends and opportunities, and any further data you may need to thrive in the omeprazole industry. This omeprazole market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Omeprazole is a proton pump inhibitor used to manage acid reflux, stomach ulcers, and other conditions associated with excessive stomach acid production. It functions by irreversibly inhibiting the H⁺/K⁺-ATPase enzyme system, also known as the proton pump, in gastric parietal cells, thereby decreasing gastric acid secretion.

The primary dosage forms of omeprazole include capsules, powders, and tablets. Capsules are solid dosage forms in which the medication is enclosed within a soluble shell or container, typically made of gelatin. Omeprazole is prescribed for the treatment of various conditions such as duodenal ulcers, gastric ulcers, gastroesophageal reflux disease, erosive esophagitis, and others, and is distributed through multiple channels including hospital pharmacies, retail pharmacies, and online pharmacies.

The omeprazole market consists of sales of delayed-release capsules, oral disintegrating tablets, and oral suspensions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.